TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05649241

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine patch
Description: Nicotine replacement therapy patch

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine patch
Description: Nicotine replacement therapy patch

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine patch
Description: Nicotine replacement therapy patch

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine patch
Description: Nicotine replacement therapy patch

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine patch
Description: Nicotine replacement therapy patch

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine patch
Description: Nicotine replacement therapy patch
Study: NCT05292508

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: C-reactive Protein Rapid Diagnostic Test
Description: In the intervention arm in addition to Usual Standard of Care, CRP Testing will be performed. In this test, health worker at health post will prick the finger of the patient using a lancet device following aseptic precautions. A very small drop (10 microliters) of whole blood will be obtained. This will be added to specimen dilution buffer. Then the sample will be mixed by inverting the tube upside down 10-15 times. Then the yellow dip area of the dipstick will be placed into the diluted sample. It will be held there until the liquid rises to the result area by capillary action. The the dipstick is removed from the solution and placed in a horizontal position. The timer will be started and result will be interpreted in 5 minutes. Treatment decision making regarding the use of antimicrobials will be conducted with the help of CRP test results and other clinical features.
Study: NCT05652972

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control diet
Description: 1700 kcal standard diet (fat: protein: carbohydrate ratio of 20:30:50)
Study: NCT05444985

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pain Management
Description: Regional anesthetic techniques for peri-operative pain management after surgery.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain Management
Description: Regional anesthetic techniques for peri-operative pain management after surgery.
Study: NCT05649241

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine patch
Description: Nicotine replacement therapy patch
Study: NCT04880265

Intervention type: DEVICE
Intervention: BraveHeart wearable life sensors
Description: Collection of EKG data
Study: NCT05803369

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Regulating Together (RT)
Description: Regulating Together is an intensive outpatient group treatment targeting emotion dysregulation. It engages both caregivers and children and utilizes evidence-based intervention techniques including cognitive behavioral therapy (CBT), visuals, reinforcements, and scaffolding, and newer interventions such as mindfulness and acceptance-based therapy.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Achieving Independence and Mastery in School (AIMS)
Description: AIMS is a school-based program developed to help students with social-communication challenges (such as autism spectrum disorder) achieve academic success. It is well-established and has been used with autistic youth, both in schools and in outpatient settings.
Study: NCT06055127

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: osseodensifiction internal sinus lift / sticky bone graft material
Description: The osteotomy for the osseodensification internal sinus lift begins with a twist drill advanced at 800 rpm with saline irrigation to within 1-2 mm from the sinus floor. Next, a series of osteotomy drills are used in the same fashion at 800 rpm to widen the osteotomy. The final osteotomy drill is advanced with gentle pressure at 100 rpm counterclockwise without irrigation until a bouncing sensation occurs haptic feedback at this point infracture of the sinus has taken place. After infracture, injection of the graft material into the osteotomy site will occur. The final osteotomy drill is used to guide the graft apically. This process is repeated in an incremental fashion to lift the membrane. Once enough space has been created below the antral membrane, implant insertion will occur then suturing.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: piezoelectric internal sinus lift / sticky bone graft material
Description: In the PISE technique, an ultrasonic piezoelectric device (acteon), to which a specialized tip is attached, is used to break the sinus floor. Developed for sinus lift by the crestal approach, the Intralift™ Kit makes it possible to undertake dental non invasive surgery in full safety.~The diamond-coated tips, of increasing diameters (from 1.35mm to 2.80mm), are designed to drill and gradually widen the access canal to the sinus membrane. The sterile spray cools the tips down to avoid any rise in temperature, which could lead to oral tissue damage.The membrane elevation is achieved using the TKW5 by means of microcavitation. Thanks to the ultrasonic frequency modulation, the risk of membrane damage is limited. Moreover, the cavitation effect enables excellent visibility of the operating field.
Study: NCT05491447

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMX-010
Description: Ointment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMX-010
Description: Ointment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Ointment
Study: NCT00012883

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Homewalking exercise program
Study: NCT05594212

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Abdominal breathing training
Description: In the sleep center, it is carried out in a one-on-one manner by the trainer. At home, self-training through abdominal breathing training videos (10 minutes per day, you can accumulate up to 10 minutes in divided doses)
Study: NCT06202001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan, Trifluridine/tipiracil (TAS-102) plus Bevacizumab
Description: This study followed a classic 3+3 design, in which patients received escalating doses of TAS-102 (20, 25, 30, or 35 mg/m2/dose, administered twice daily for days 1-5) and irinotecan (135, 150, 165, or 180 mg/m2 on day 1) with a fixed dose of bevacizumab (5 mg/kg on day 1), repeated every 14 days.
Study: NCT05649241

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine patch
Description: Nicotine replacement therapy patch

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine gum
Description: Nicotine replacement therapy gum

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine gum
Description: Nicotine replacement therapy gum

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine gum
Description: Nicotine replacement therapy gum

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine gum
Description: Nicotine replacement therapy gum

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medication Therapy Management
Description: Medication therapy management delivered by pharmacist - 1 in-person coaching session, and 5 follow-up telephonic coaching sessions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medication Therapy Management
Description: Medication therapy management delivered by pharmacist - 1 in-person coaching session, and 5 follow-up telephonic coaching sessions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medication Therapy Management
Description: Medication therapy management delivered by pharmacist - 1 in-person coaching session, and 5 follow-up telephonic coaching sessions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medication Therapy Management
Description: Medication therapy management delivered by pharmacist - 1 in-person coaching session, and 5 follow-up telephonic coaching sessions.
Study: NCT05325593

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: romiplostim plus dexamethasone
Description: Patients will be reviewed weekly for 8 weeks (56 days). After Week 8, patients will be reviewed every 2 weeks (14 days) for 8 additional weeks and then monthly until Week 52 (365 days) from randomization.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Patients will be reviewed weekly until the completion of dexamethasone cycles and for a minimum of 8 weeks (56 days). After that, every 2 weeks (14 days) for 8 additional weeks and then monthly until Week 52 (365 days) from randomization.
Study: NCT06197958

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: eccentric exercises
Description: eccentric exercises like walking down stairs, lowering a weight during shoulder press, the downward motion of squatting, the downward motion of a push-up, lowering the body during a crunch, lowering the body during a pull-up 3 sets with 10 RM (repetition maximum) for six week training.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: concentric exercises
Description: concentric exercises like walking upstairs, pushing up in a bench press, the beginning portion of a deadlift when you lift the barbell off the ground, sitting up in a sit up, pushing up from a lowered push-up and standing up in a back squat 3 sets with 10 RM.
Study: NCT04740814

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol
Description: * Pharmaceutical form: Solution for injection~* Route of administration: Subcutaneous Subjects will receive certolizumab pegol in a pre-specified sequence during the study.
Study: NCT05737316

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combat PD
Description: CombatPD is an aerobic exercise programme hosted on a mobile application that pairs with motion sensors and heart rate monitor, which connects to a web-based portal for remote monitoring. The wearable sensors consist of (i) 2 motion sensors worn across one thigh and attached to an exercise ring which is held by the participant during the exergame and (ii) 1 heart rate sensor worn across the participant's chest. They will receive once weekly physiotherapy sessions at the study site for the first 4 weeks where they will be guided through the use of the CombatPD. Participants will be instructed to perform 2 sessions of 30-minute exergames in addition to a session of 30-minute brisk walking every week for 12 weeks at home. They will be instructed to exercise at a target heart rate zone at moderate intensity (i.e., 40% - 60% Heart Rate Reserve), which will be gradually increased.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Participants in the control group (usual care) will receive once weekly physiotherapy sessions for first 2 weeks and another session at week 6 where they will be taught home exercises based on a standard PD exercise booklet, consisting mainly of range of motion and stretching exercises , as well as brisk walking techniques. Participants in the control group will be instructed to perform these home exercises twice a week, in addition to a 30-minute brisk walk for 12 weeks.
Study: NCT01288625

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amifostine
Description: 500 mg sc, qod, 3 times per week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amifostine
Description: 500 mg sc, qod, 3 times per week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amifostine
Description: 500 mg sc, qod, 3 times per week

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Amifostine
Description: 500mg rinsing wash, qod, 3 times per week

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Amifostine
Description: 500mg rinsing wash, qod, 3 times per week

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Amifostine
Description: 500mg rinsing wash, qod, 3 times per week
Study: NCT05643248

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NEX-20A
Description: Subcutaneous prolonged-release injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NEX-20A
Description: Subcutaneous prolonged-release injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NEX-20A
Description: Subcutaneous prolonged-release injection
Study: NCT05065307

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Venipuncture
Description: Diagnostic venipuncture

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Venipuncture
Description: Diagnostic venipuncture
Study: NCT05750316

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cowpea leaves mixed with Jam
Description: 6g of freeze-dried cowpea leaves, equivalent to 80g(a portion) of vegetables mixed with Jam and spread on bread

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jam mixed with green food colour
Description: Jam with green food colouring spread on bread
Study: NCT05506917

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: periodontal treatment
Description: Patients will receive an intensive (non surgical) regimen of scaling and root planing of the root surfaces under local analgesia (depending on the severity in one session or two sessions within 2 days). Any tooth that from the baseline examination is defined as hopeless or irrational to treat will be extracted at the oral hygiene visit. After the 2 months re-assessment individuals if presenting with at least one periodontal pocket of 6 mm in depth will undergo additional corrective periodontal therapy consisting of periodontal surgery and re-instrumentation under local analgesia. If surgical periodontal therapy is not indicated, appropriate re-instrumentation of the sites will be performed.
Study: NCT04679441

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: The Computerized Functional Skills Assessment and Training Program
Description: The CFSAT program provides training on everyday tasks critical to independent living (e.g., financial and medication management). The program currently includes six domain simulations critical to independent living: ATM Banking/Financial Management, Online Banking, Prescription Refill via Voice Menu, Kiosk Ticket Purchase, Online Shopping (and prescription refill), and Medication Management.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Computerized Functional Skills Assessment and Training Program
Description: The CFSAT program provides training on everyday tasks critical to independent living (e.g., financial and medication management). The program currently includes six domain simulations critical to independent living: ATM Banking/Financial Management, Online Banking, Prescription Refill via Voice Menu, Kiosk Ticket Purchase, Online Shopping (and prescription refill), and Medication Management.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Computerized Functional Skills Assessment and Training Program
Description: The CFSAT program provides training on everyday tasks critical to independent living (e.g., financial and medication management). The program currently includes six domain simulations critical to independent living: ATM Banking/Financial Management, Online Banking, Prescription Refill via Voice Menu, Kiosk Ticket Purchase, Online Shopping (and prescription refill), and Medication Management.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Brain HQ Double Decision
Description: Cognitive speed training program
Study: NCT06317922

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thealoz Duo;
Description: THEALOZ DUO is a solution containing trehalose (3%), sodium hyaluronate (0.15%), sodium chloride, trometamol, hydrochloric acid, and water for injections; Hydraback is a solution containing a sodium chloride 0.9 %, sodium dihydrogen phosphate dihydrate, sodium phosphate dodecahydrate, water for preparations for injection.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: sham (Hydrabak)
Description: Hydrabak is an ophthalmic solution containing: sodium chloride 0.9%, sodium dihydrogen phosphate dihydrate, sodium phosphate dodecahydrate, and water for injectable preparations
Study: NCT06527196

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Team Communication Training
Description: Participants in the experimental arm will receive enhanced Team Communication Training developed during Aim I of the trial. This will occur over a period of six months.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Early Identification Universal Depression Screening
Description: Providers in the early identification universal depression screening condition will be asked to continue communications and response to depression screening as currently implemented.
Study: NCT06528808

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simple reality simulator application
Description: Women in the intervention group will be given an application aimed at breast cancer awareness with a simple valid simulator.
Study: NCT05561894

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: pulse pressure variation index guided fluid therapy
Description: maintainence intraoperative fluid therapy (ringer's acetate) will be given guided by either two goals of pulse pressure variation index, either \>12% or \>16%

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: pulse pressure variation index guided fluid therapy
Description: maintainence intraoperative fluid therapy (ringer's acetate) will be given guided by either two goals of pulse pressure variation index, either \>12% or \>16%
Study: NCT05350540

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ICG dye
Description: Patients assigned to the intervention group will undergo surgery guided by tissue perfusion as directed by the ICG imaging
Study: NCT06199024

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral cinnamon supplementation
Description: In intervention group patients will take 1500 mg daily (3 tablets of cinnamon 500 mg, Sagepad Darou Pharmaceutical Company, Iran) that is, 4 weeks before the start of the new IVF cycle and 2 weeks during the ovarian stimulation process.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Oral cinnamon supplementation
Description: In intervention group patients will take 1500 mg daily (3 tablets of cinnamon 500 mg, Sagepad Darou Pharmaceutical Company, Iran) that is, 4 weeks before the start of the new IVF cycle and 2 weeks during the ovarian stimulation process.
Study: NCT05497661

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 448kilohertz Capacitive Resistive Radiofrequency Stimulation in a Sporty Population.
Description: 448kilohertz Capacitive Resistive Radiofrequency Stimulation on Patellar tendon in a Sporty Population.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo comparator
Description: To simulate a 448kilohertz capacitive resistive monopolar radiofrequency application on the non dominant patellar tendon

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: To simulate a 448kilohertz capacitive resistive monopolar radiofrequency application on the non dominant patellar tendon
Study: NCT06261112

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: kaleidescope
Description: used to kaleideskope
Study: NCT06279663

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Revascularization
Description: revascularization

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Revascularization
Description: revascularization
Study: NCT05279716

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eybelis ophthalmic solution 0.002%
Description: Ophthalmic eye drop
Study: NCT06492317

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disitamab Vedotin
Description: Disitamab Vedotin: 2.5mg/kg, d1, ivdrip, Q2W (every 2 weeks)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cadonilimab
Description: Cadonilimab: 6mg/kg, d1, ivdrip, Q2W (every 2 weeks)
Study: NCT05344170

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 30 mg Cannabinol (CBN)
Description: Participants will receive a 2 mL oral dose of 'ECS 310' (1.5%), an oral formulation of CBN (15 mg/mL) suspended in medium chain triglycerides (MCT) oil.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 300 mg Cannabinol (CBN)
Description: Participants will receive a 2 mL oral dose of 'ECS 310' (15%), an oral formulation of CBN (150 mg/mL) suspended in medium chain triglycerides (MCT) oil.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive a 2 mL oral dose of placebo. Placebo contains the same excipient, medium chain triglycerides (MCT) oil, as the investigational products but does not contain cannabinoids.
Study: NCT05488730

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: passive leg raising test and fluid challenge
Description: Shocked patients were subjected to echocardiographic examination if (EF \<52%) .baseline LVOT VTI was obtained Then IVC scanning was done through subcostal Window and using M-mode the minimum and the maximum diameters were measured then the collapsibility index was calculated~Then passive leg raising test was done Patients who tolerated the PLR test and did not develop clinical or lung ultrasound signs of fluid overload (lung congestion) were given IV fluid bolus (250 ml normal saline) over 10 minutes followed by measurement of LVOT VTI.~Patients who did not tolerate PLR test or developed clinical or lung ultrasound signs of fluid overload (lung congestion) during PLR test were excluded from the third step (fluid challenge).~The differentiating factor used to allocate patient in which group (non-responder or responder) was LVOT VTI variability after fluid challenge (our gold standard to assess fluid responsiveness).
Study: NCT05163236

Intervention type: DIAGNOSTIC_TEST
Intervention: Positive fecal immunochemical test (FIT)
Description: We evaluated CRCs screening campaign from January 1, 2016 to December 31, 2017, and interval cancers within two years after a negative test, and five years for post-colonoscopy interval cancers.

Intervention type: DIAGNOSTIC_TEST
Intervention: Positive fecal immunochemical test (FIT)
Description: We evaluated CRCs screening campaign from January 1, 2016 to December 31, 2017, and interval cancers within two years after a negative test, and five years for post-colonoscopy interval cancers.

Intervention type: DIAGNOSTIC_TEST
Intervention: Positive fecal immunochemical test (FIT)
Description: We evaluated CRCs screening campaign from January 1, 2016 to December 31, 2017, and interval cancers within two years after a negative test, and five years for post-colonoscopy interval cancers.

Intervention type: DIAGNOSTIC_TEST
Intervention: Negative fecal immunochemical test (FIT)
Description: We evaluated CRCs screening campaign from January 1, 2016 to December 31, 2017, and interval cancers within two years after a negative test, and five years for post-colonoscopy interval cancers.